Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022
Rain Therapeutics Inc. (NASDAQ: RAIN) will announce its Q2 financial results on August 4, 2022, at 2:00 PM PT. The company is focused on precision oncology therapeutics, particularly its lead candidate, milademetan, which targets oncogenic drivers. The announcement will include a conference call to discuss financial results and recent progress. Investors can access a replay via the company’s website afterwards. Rain Therapeutics is committed to genetically selecting patients for its therapies, enhancing treatment specificity in cancer care.
- Upcoming financial results expected on August 4, 2022, indicating ongoing transparency and communication with investors.
- Focus on precision therapies, potentially enhancing treatment outcomes in oncology.
- None.
NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter ended June 30, 2022 and highlights of recent progress on Thursday, August 4, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: August 4, 2022
Time: 2:00 PT (5:00 pm ET)
Dial In Numbers: 1 (888) 394-8218 (U.S. Toll Free) / 1 (323) 701-0225 (International)
Conference ID: 1307426
Webcast Link: https://edge.media-server.com/mmc/p/tvv3pskx
Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
FAQ
What is Rain Therapeutics' upcoming financial announcement date?
What is the focus of Rain Therapeutics' business?
What is the lead product candidate of Rain Therapeutics?
How can investors access the financial results call?
What is the strategy employed by Rain Therapeutics for patient selection?
